Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Valneva Austria GmbH is managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, indicating a variety of individual perspectives on the company's filings. However, these examiners are grouped within only 2 distinct art units, suggesting some level of technical consistency in the review process.
CHESTNUT, BARRY A is the busiest examiner, currently handling 1 pending action. This distribution requires the company to manage 4 different examiner relationships across 2 specialized units. Practitioners should look for commonalities in the policies of the two art units while addressing the unique concerns of each examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| MORGAN, BAILEY MICHELLE | 1 | 56.3% | +58.3% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| WANG, RUIXUE | 1 | 55.9% | +19.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17688960 | INACTIVATION PROCESS FOR VIRUSES | WANG, RUIXUE | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17688960 | INACTIVATION PROCESS FOR VIRUSES | WANG, RUIXUE | 34d |
| 17917010 | IMPROVEMENTS IN VACCINE FORMULATIONS FOR MEDICAL USE | MORGAN, BAILEY MICHELLE | — |
| 17932226 | MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| 1645 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18799291 | Zika Virus Vaccine | CHESTNUT, BARRY A | 1672 | §102§103DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 17917010 | IMPROVEMENTS IN VACCINE FORMULATIONS FOR MEDICAL USE | MORGAN, BAILEY MICHELLE | 1645 | §112 | Non-Final OA | — | Pending | Oct 05, 2022 |
| 17932226 | MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO | DUFFY, PATRICIA ANN | 1645 | DP | Non-Final OA | — | Pending | Sep 14, 2022 |
| 17688960 | INACTIVATION PROCESS FOR VIRUSES | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | 34d | Pending | Mar 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialValneva Austria GmbH has 4 pending office actions as of October 2026, spread across 2 art units and 4 examiners.
Barry A Chestnut has the most, with 1 of Valneva Austria GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
